[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taipei Medical University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":176},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,74,98,122,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641272","phase-2-aumolertinib-combined-with-phased-chemotherapy-for-egfr-l858r-lung-adenocarcinoma-100641272",false,"NCT07624487","Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma","A Phase II Study of Aumolertinib Combined With Phased Chemotherapy for Treatment-Naïve EGFR L858R-Mutated Lung Adenocarcinoma (ACCEL Trial)","Inclusion Criteria:\n\n1. Individuals must be at least 18 years of age at the time of signing the informed consent form.\n2. Participants must demonstrate the ability to understand the study procedures and provide written informed consent before any trial-specific activities begin.\n3. A confirmed diagnosis of lung adenocarcinoma (LUAD) via histological or cytological examination is required. The disease must be in an advanced or metastatic stage (stage IIIB, IIIC, or IV by AJCC TNM staging system 9th edition) that is not suitable for curative-intent surgery or radiation therapy.\n4. Documentation of an EGFR L858R mutation is mandatory. This status can be confirmed using tumor tissue or plasma-based molecular testing.\n5. Participants must not have received prior systemic therapy for advanced or metastatic LUAD. Previous adjuvant or neoadjuvant treatments are allowed if they were completed at least 12 months before the first dose of the study medication.\n6. An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 is required. The estimated life expectancy of the participant must be at least three months.\n7. Participants must have at least one measurable lesion that has not been previously irradiated, as defined by RECIST 1.1 criteria.\n8. Adequate physiological function must be demonstrated within 14 days before the start of treatment, including:\n\n   Bone Marrow: Absolute neutrophil count ≥ 1.5 x 10\\^9\u002FL, platelet count ≥ 100 x 10\\^9\u002FL, and hemoglobin ≥ 9.0 g\u002FdL.\n\n   Hepatic: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present.\n\n   Renal: Serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 45 mL\u002Fmin.\n9. Reproductive Safety: Participants of childbearing potential must agree to use highly effective contraception throughout the study and for a specified period after the final dose of the investigational products\n\nExclusion Criteria:\n\n1. Any previous treatment with EGFR tyrosine kinase inhibitors, including first-, second-, or third-generation agents (e.g., gefitinib, afatinib, or osimertinib).\n2. Patients with symptomatic or unstable central nervous system metastases. However, participants with symptomatic or unstable brain metastases who have completed local treatment and are off high-dose corticosteroids (\\>10 mg\u002Fd prednisone or equivalent) for at least two weeks may be considered eligible.\n3. Severe Comorbidities:\n\n   Cardiac: History of clinically significant cardiovascular disease, such as uncontrolled hypertension, congestive heart failure (NYHA Class II or higher), or a recent myocardial infarction within the last six months.\n\n   Pulmonary: Known history of interstitial lung disease (ILD) or drug-induced ILD that required steroid treatment.\n\n   Gastrointestinal: Malabsorption syndromes or chronic inflammatory bowel disease that could interfere with the absorption of oral aumolertinib.\n4. Concomitant Infections: Active infections requiring systemic therapy. Patients with HBV infection may be eligible if their have received adequate antiviral treatment (antiviral treatment ≥ 7 days before the first dose of the study medication).\n5. Medication Interference: Ongoing use of potent CYP3A4 inhibitors or inducers, as these may significantly alter the plasma concentrations of aumolertinib.\n6. Other Malignancies: A history of another active primary malignancy within the last three years, except for adequately treated non-melanoma skin cancer or in situ carcinoma elsewhere.\n7. Hypersensitivity: Known hypersensitivity to aumolertinib, pemetrexed, carboplatin, or any of the excipients used in these formulations.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Background: While third-generation EGFR tyrosine kinase inhibitors (TKI) like aumolertinib have significantly improved outcomes for patients with advanced lung adenocarcinoma, those harboring the L858R mutation still experience inferior prognosis compared to those with exon 19 deletions. Recent evidence suggests that combining TKIs with chemotherapy improves progression-free survival (PFS), but universal application of this combination exposes all patients to cytotoxic toxicity, even those who might thrive on TKI monotherapy alone. Circulating cell-free DNA (cfDNA) and minimal residual disease monitoring offer a dynamic window to identify which patients truly require treatment intensification.\n\nObjectives: The primary objective is to evaluate the predictive value of early molecular response by determining the association between the change in EGFR mutant allele fraction in cfDNA after a 6-week aumolertinib lead-in induction phase (T1) and a 4-cycle combination chemotherapy (T2) with clinical PFS. Secondary objectives include assessing overall response rates (ORR), disease control rate (DCR), safety, and the dynamics of EGFR mutant allele fraction and circulating immune cell profiles.\n\nStudy Design: This is a prospective, single-arm, multicenter, phase II clinical trial enrolling 50 evaluable patients. The study utilizes a three-phase treatment framework:\n\n* Induction Phase: Aumolertinib monotherapy (110 mg\u002Fday) once daily for 6 weeks.\n* Consolidation Phase: Combination of aumolertinib (110 mg\u002Fday) once daily with pemetrexed (500 mg\u002Fm²) and carboplatin (AUC 5) once every three weeks for 4 cycles.\n* Maintenance Phase: Aumolertinib monotherapy once daily until disease progression.\n\nEndpoints: The primary efficacy endpoint is Progression-Free Survival (PFS). Molecular efficacy will be measured via the Molecular Clearance Rate (MCR) and Molecular Response Rate (MRR) at baseline (T0), post-induction (T1), and post-chemotherapy (T2). Safety will be graded according to CTCAE v5.0.\n\nConclusion and Significance: This trial aims to establish a molecularly driven framework for personalized lung cancer management, seeking to maximize efficacy for high-risk patients while providing the foundation to spare molecular responders from unnecessary chemotherapy in the future. The results will serve as the base for the design of future confirmatory phase III trials.",[26],"Lung Adenocarcinoma Metastatic",[28,29,30,31],"Lung adenocarcinoma","EGFR L858R","EGFR-TKI","Chemotherapy","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":20},"2026-06-09",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"Taipei Medical University Hospital","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100615581","phase-2-menthol-for-improving-movement-and-sleep-in-parkinsons-disease-patients-100615581","NCT07294469","Menthol for Improving Movement and Sleep in Parkinson's Disease Patients","Effect of Menthol on Motor Deficits and Sleep Disturbances in Patients With Parkinson's Disease","Inclusion Criteria:\n\n1. aged between 30 and 80 years (inclusive);\n2. diagnosed with idiopathic PD based on the Brain Bank criteria of the UK Parkinson's Disease Society less than 3 years;\n3. Hoehn and Yahr stages 1-3 and currently receiving treatment; experiencing sleep disorders with a Pittsburgh Sleep Quality Index (PSQI) \\> 5;\n4. has signed the informed consent form approved by the Institutional Review Board and dated accordingly;\n5. no changes in PD medications within four weeks prior to participating in this trial, and no dosage changes during the study period;\n6. able to use other medications that may affect sleep, except those explicitly prohibited, provided the dosage has been stable for the four weeks before screening and remains unchanged during the study.\n\nExclusion Criteria:\n\n1. menthol allergy;\n2. pregnant and breastfeeding women;\n3. diagnosed with secondary and atypical PD;\n4. patients with conditions such as uremia, cirrhosis, congestive heart failure with pulmonary edema, coagulation disorders, epilepsy, alcoholism, drug abuse, or\n5. deemed unsuitable for participation in this study by the principal investigator.","30 Years","80 Years",{"count":55,"type":20},80,[23],"Parkinson's disease (PD) is a progressive neurological disorder characterized by both motor and non-motor symptoms due to the degeneration of dopamine-producing neurons. There is currently no cure. Menthol, a natural compound that activates TRPM8 receptors, has shown neuroprotective and motor function benefits in preclinical PD models. In mice, distal limb immersion in menthol improved dopamine neuron survival and motor performance. Similar menthol-based interventions improved outcomes in a stroke model and a clinical trial with stroke patients. This study investigates whether topical menthol can offer therapeutic benefits for individuals with PD.",[59],"Parkinson's Disease",[61,59,62,63],"Menthol","Motor Deficits","Sleep Disturbances","NOT_YET_RECRUITING","2026-01-05",{"date":67,"type":36},"2026-01-08",{"date":69,"type":20},"2025-12-15",{"date":71,"type":20},"2027-07-31",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":73},"100601730","spontaneous-breathing-trials-using-pressure-support-or-t-piece-in-overweight-and-obese-patients-100601730","NCT07114289","Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients","Comparison of Pressure Support Ventilation and T-Piece as Spontaneous Breathing Trials Before Extubation Among Obese and Overweight Patients","Inclusion Criteria:\n\n1\\. Patients had undergone intubation and mechanical ventilation for more than 24 hours prior to the first spontaneous breathing trial.\n\n2\\. Adult patients aged ≥ 18 years. 3. BMI ≥ 25 kg\u002Fm². 4. Meeting all the Inter national Consensus Conference on weaning criteria:\n\n1. Stable vital signs: heart rate \\\u003C 140 beats\u002Fmin, systolic blood pressure: 90-160 mmHg, and no use of vasopressors or use of minimal doses (\\\u003C0.2 µg\u002Fkg per min).\n2. Respiratory rate ≤ 35 breaths\u002Fmin.\n3. Adequate oxygenation, defined as either SpO2 \\> 90% with FiO2 ≤ 0.4, or PaO2\u002FFiO2 \\> 150 mmHg with positive end-expiratory pressure (PEEP) ≤ 8 cmH2O.\n4. Adequate cough strength (MIP \\\u003C -20 cmH2O).\n5. An awake state, defined as a score of Richmond Agitation-Sedation Scale between +1 and -2, or Glasgow Coma Scale \\> 8.\n6. No continuous sedation. 5. Informed consent provided by the patient or their relatives.\n\nExclusion Criteria:\n\n1. Patients with tracheostomy.\n2. Patients who had been admitted for traumatic brain injury.\n3. Patients who had preexisting peripheral neuromuscular disease (underlying myopathy or myasthenia gravis).\n4. Patients who had a do-not-reintubate order at the time of the initial spontaneous breathing trial were excluded\n5. Patients who have already undergone a first spontaneous breathing trial.\n6. Patients who had undergone extubation without an SBT\n7. Protected populations: pregnant or breastfeeding women, individuals under guardianship, or those under legal protection.\n8. Patients who refused to participate during the study.",{"count":82,"type":20},100,[84],"NA","This study aims to find out which method of spontaneous breathing trial (SBT) better helps overweight and obese ICU patients prepare for extubation, which is the removal of the breathing tube. The two methods being compared are pressure support ventilation (PSV) and the T-piece.\n\nParticipants are adults with a body mass index (BMI) of 25 or higher who have been on a breathing machine (invasive mechanical ventilation) for more than 24 hours. Before removing the breathing tube, participants will be randomly assigned to receive either a PSV or a T-piece trial for 1 hour. After that, doctors will decide if they are ready for extubation.\n\nThe main question this study wants to answer is: Which method leads to a higher rate of successful extubation-defined as not needing to be reintubated within 72 hours?",[87,88,89,90],"Mechanical Ventilation","Extubation","Obesity &Amp; Overweight","Respiratory Failure","2025-11-13",{"date":93,"type":36},"2025-11-17",{"date":95,"type":36},"2025-09-29",{"date":71,"type":20},{"name":42,"class":43},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":73},"100589069","repetitive-transcranial-magnetic-stimulation-in-cancer-pain-management-100589069","NCT06949618","Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management","Feasibility and Effectiveness of Repetitive Transcranial Magnetic Stimulation in Patients With Cancer Pain","Inclusion Criteria:\n\n1. Patients have cancer pain symptoms, confirmed by a physician as cancer pain or neuropathic cancer pain\n2. Experienced the worst pain NRS score ≥ 4\n3. The patient demonstrate good cognition and is able to cooperate with the assessment of pain severity.\n4. The estimated survival time exceeds 3 months.\n5. Pre-existing bisphosphonate, chemotherapy, and hormonal therapy regimens remained unchanged throughout the study.\n\nExclusion Criteria:\n\n1. Individuals who have undergone head surgery or have metal implants in the head.\n2. Individuals with implanted cardiac pacemakers or cochlear prostheses.\n3. Have a history of epilepsy.\n4. Patients diagnosed with primary brain tumors or metastatic brain lesions.\n5. Present with additional neurological, psychiatric, or severe medical disorders.\n6. Individuals with metallic implants located in the cranial or cervical regions.\n7. Women who are pregnant.\n8. Presence of acute pain in any body region attributable to other medical conditions. -","20 Years","70 Years",{"count":108,"type":20},30,[84],"Over half of cancer patients experience cancer-related pain. Despite advances in pain management with opioids, many patients continue to suffer from chronic cancer pain. The underlying mechanisms of cancer-related pain remain poorly understood, but they may be linked to brain neuroplasticity. As a result, some researchers suggest that targeting the motor cortex in cancer patients could improve pain management. However, few studies have investigated the effectiveness of remodeling neuroplasticity with repetitive transcranial magnetic stimulation (rTMS) to reduce cancer-related pain. To validate the use of rTMS in cancer-related pain, we plan to conduct a randomized controlled trial involving 30 cancer pain patients. Participants will be randomly assigned to receive either rTMS or sham rTMS treatment. Functional magnetic resonance imaging (fMRI) and pain index assessments will be conducted before and after the treatment to evaluate the outcomes.",[112,113],"Pain","Cancer","2025-05-14",{"date":116,"type":36},"2025-05-18",{"date":118,"type":20},"2025-05-20",{"date":120,"type":20},"2026-12-30",{"name":42,"class":43},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":73},"100298727","mrgfus-and-rfa-for-treatment-of-facet-joint-osteoarthritis-low-back-pain-100298727","NCT03168802","MRgFUS and RFA for Treatment of Facet-joint Osteoarthritis Low Back Pain","Comparative Study of Magnetic Resonance-guided Focused Ultrasound and Radiofrequency Ablation for Treatment of Facet-joint Osteoarthritis Low Back Pain","Inclusion Criteria:\n\n1. Men and women age 20 to 79 years old\n2. Suffering from lumbar vertebral facet joint syndrome.\n3. Lower back pain at least six months (NRS≥4).\n4. Conventional treatment of pain includes NSAIDs, opioids, muscle relaxants, oral steroids, physical therapy or chiropractic therapy.\n5. Imaging of the spine have facet osteoarthritis.\n6. Referred pain is no more below the knee.\n7. At least once when local anesthesia or diagnostic medial nerve branch injection, pain reduction\\> 75% (0.5ml of 2% lidocaine).\n\nExclusion Criteria:\n\n1. Patients with evidence of lumbosacral radiculopathy on MRI, CT or physical exam findings, including radicular leg pain.\n2. Patients with motor deficit or any other indication for surgical intervention.\n3. Patients with MRgFUS or RF treatment for LBP within the last 6 months.\n4. Patients with previous low back surgery.\n5. Patients who are pregnant.\n6. Patients with existing malignancy.\n7. Patients with allergies to relevant contrast, anesthetics, sedation drugs.\n8. Patients with contraindications for MRI.\n9. Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.\n10. Patients with unstable cardiac status including:\n\n    * Unstable angina pectoris on medication\n    * Patients with documented myocardial infarction less than 40 days prior to protocol enrolment\n    * Patients with Severe Congestive Heart Failure, NYHA class 4.\n    * Patients on anti-arrhythmic drugs or with uncontrolled and\u002For untreated arrhythmia status\n    * Patients with pacemaker\n11. Patients with severe cerebrovascular disease (CVA within last 6 months)\n12. Patients with severe hypertension (diastolic BP \\> 100 on medication)\n13. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.\n14. Patients unable to communicate with the investigator and staff.\n15. Patients who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)\n16. Coagulation disorders or other bleeding disorders, use of anticoagulants or antiplatelet drugs within 5 days before treatment.\n17. When local anesthesia or diagnostic medial nerve branch injection, the pain does not reach 75% (0.5 mL of 2% lidocaine).","79 Years",{"count":82,"type":20},[84],"This is a prospective, randomized, two-arm, phase II study.\n\nThe purpose of this study is:\n\n* To evaluate and compare the efficacy and safety of magnetic resonance-guided focused ultrasound (MRgFUS) and radiofrequency ablation (RFA) for treatment of facet-joint osteoarthritis low back pain.\n* Determining the effect of the MRgFUS System and RFA for improving functional disabilities and in reducing pain resulting from facet-joint osteoarthritis low back pain. Efficacy will be determined by the level of pain relief (as measured by the Numerical Rating Scale, NRS), decrease in analgesics\u002Fopiate, improved quality of life (as measured by the Oswestry Disability Questionnaire, ODQ, and core outcome measures index questionnaire, COMI), pain interference with function (as measured by the Brief Pain Inventory-Interference scale, BPI-QoL), general health status (as measured by the EQ5D), physical exam, X-ray and MRI studies from baseline up to 12-Months post- MRgFUS and radiofrequency treatment.\n* Evaluate incidence and severity of adverse events associated with the MRgFUS system and RFA used for the treatment of pain resulting from facet-joint osteoarthritis low back pain.",[134,135],"Chronic Low Back Pain","Facet Joint Syndrome",[137,138,139,140],"Focused ultrasound Ablation","Radiofrequency Ablation","Facet joint syndrome","Chronic low back pain","2024-12-03",{"date":143,"type":36},"2024-12-05",{"date":145,"type":36},"2018-08-24",{"date":147,"type":20},"2025-11-25",{"name":42,"class":43},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":73},"100490512","effects-of-multiple-mega-dose-of-vitamin-d3-supplementation-on-ameliorating-moderate-to-severe-chronic-pain-in-hemodialysis-patients-100490512","NCT05667090","Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients","Inclusion Criteria:\n\n1. Haemodialysis subject ≥ 20 years old\n2. iPTH \\> 250 pg\u002FmL\n3. Chronic pain with visual analogue scale (VAS) score ≥ 4\n4. Voluntary to check serum 25(OH)D levels two times by his\u002Fher own payment during the study\n5. Sign the informed consent\n\nExclusion Criteria:\n\n1. Used to participate in other clinical trials\n2. Chronic liver disease\n3. Sarcoidosis or multiple myeloma",{"count":156,"type":20},120,[84],"Pain is a major complaint in hemodialysis (HD) patients. Concentrations of parathyroid hormone (PTH) \\>250 pg\u002Fml are associated with chronic pain. Visual Analogue Scale (VAS) score which is used to assess the pain severity is positively related to PTH levels. This study is aimed to assess the effects of multiple mega dosages vitamin D supplementations in HD patients with chronic pain. It's a single-center, parallel, double-blind randomized control trial that administrations of 576,000 IU once a week of vitamin D3 for 4 weeks or placebo are for 120 eligible subjects. VAS and laboratory tests including serum concentrations of 25(OH)D, calcium, phosphorus, PTH and C-reactive protein will be evaluated.",[160,161,162],"Hemodialysis","Chronic Pain","Hyperparathyroidism",[164,165,166,167],"Vitamin D supplementation","Mega-dose vitamin D","Cholecalciferol","Chronic pain","2023-03-29",{"date":170,"type":36},"2023-03-30",{"date":172,"type":36},"2023-03-15",{"date":174,"type":20},"2027-12-31",{"name":42,"class":43},""]